EFS-Web Receipt date: 02/2002
FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE
(REV. 7-85)
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC NO. 4-30944A/C1 APPLICATION NO. 10/035,301 APPLICANT FRANCE ET AL. FILING DATE OCTOBER 25, 2001 shed 9935301 - GAU: 1654

Group

COPY OF PAPERS ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,538,997*	7/23/96	Billich et al.	514	510	
	AB						
	AC						
	AD						-
	AE						
	AF					-	
	AG						
	AH						
•	Al						· .
	AJ						
	AK						•,
	AL	, , , , , , , , , , , , , , , , , , , ,					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN: YES	SLATION NO
AM	WO 93/01166	01/21/93	PCT				
AN							
AO							
AP							
AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

area," pp. 5-17 (1997)*
Rolfe M. et al., J. Mol. Med., Vol. 75, "The ubiquitin-mediated proteolytic pathway as a therapeutic
André P. et al., Proc. Natl. Acad. Sci. USA, Vol. 95, "An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and i cell responses," pp. 13120-13124 (1998)

EXAMINER

/Andrew D. Kosar/

| DATE CONSIDERED

07/06/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.